Status:
COMPLETED
Galectin-3 Binding Protein in Cardiovascular Disease and Chronic Heart Failure
Lead Sponsor:
Heidelberg University
Conditions:
Heart Failure
Cardiomyopathies
Eligibility:
All Genders
Brief Summary
The purpose of this study is to determine whether galectin-3 binding protein plasma levels can predict adverse cardiovascular events in patients with coronary artery disease and/or heart failure.
Detailed Description
Chronic heart failure represents an important cause of disease burden in Western countries. Heart failure can be either caused by vascular disease (i.e. cardiomypathy (CMP) due to coronary artery dise...
Eligibility Criteria
Inclusion
- impaired ventricular function
Exclusion
- neoplastic disease
- infections with hepatitis C or HIV
Key Trial Info
Start Date :
June 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 1 2010
Estimated Enrollment :
373 Patients enrolled
Trial Details
Trial ID
NCT01210157
Start Date
June 1 2008
End Date
August 1 2010
Last Update
September 28 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Heidelberg, Dept. of Cardiology
Heidelberg, Germany, 69120